GPI and hepatocellular carcinoma: The above findings suggest that luteolin may lead to the downregulation of FLOT1 expression through the upregulation of miR-6809-5p, and that both of these expression changes may cause the inactivation of pathways such as NF-κB, thus exerting the anti-hepatocellular carcinoma cell growth effect.[87] Furthermore, in another study targeting hepatocellular carcinoma cells, Luteolin were found to exert anti-tumor effects by activating protein kinases through the activation of AMF in HepG2 cells, thereby modulating the NF-κB signaling pathway.[88]